Researchers last week provided a glimpse of the clinical performance of a trio of extraction-free molecular assays currently being developed by clinical diagnostics firm Quidel.

Specifically, in a company-sponsored corporate workshop session held in conjunction with the Association for Molecular Pathology meeting in Phoenix, Ariz., the independent investigators presented data from clinical assessments of the Quidel Molecular Group A Strep, AmpliVue Group B/C/G Strep, and Quidel Molecular HSV 1&2/VZV assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.